Courtney Marabella | Authors

April 10, 2021

Trastuzumab deruxtecan has not only demonstrated efficacy as a potential anti-HER2 therapeutic option for patients with HER2-amplified gastric cancers, but has also shown promise in those with HER2 moderate-, low-, and non-expressing disease.

March 21, 2021

Although responses were limited in patients with paclitaxel-pretreated cervical cancer, eribulin may still show promise in those who are naïve to treatment with the chemotherapy agent.

February 15, 2021

More cases of metastatic prostate cancer may be linked with a reduction in prostate-specific antigen screening, experts say.

February 14, 2021

A phase 2 SWOG trial comparing multiple therapies versus sunitinib for papillary renal cell carcinoma revealed superior activity of cabozantinib in this setting.

January 31, 2021

The phase 3 NeoADAURA trial will examine both single-agent osimertinib as well as the combination with platinum-based chemotherapy versus chemotherapy alone in the neoadjuvant setting in patients with resectable, stage II to IIIB non–small cell lung cancer whose tumors harbor EGFR mutations.

January 31, 2021

Safety and antitumor activity of mobocertinib became evident after results of a trial involving EGFR exon 20 insertion–mutant non–small cell lung cancer were reported at the 2020 World Conference on Lung Cancer Singapore.